|
1
|
Abiraterone and increased survival in metastatic prostate cancer.
|
N Engl J Med
|
2011
|
27.58
|
|
2
|
Integrative genomic profiling of human prostate cancer.
|
Cancer Cell
|
2010
|
23.61
|
|
3
|
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.
|
Nature
|
2005
|
15.83
|
|
4
|
Abiraterone in metastatic prostate cancer without previous chemotherapy.
|
N Engl J Med
|
2012
|
15.69
|
|
5
|
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
|
Clin Cancer Res
|
2008
|
14.37
|
|
6
|
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
|
Science
|
2009
|
13.87
|
|
7
|
Enzalutamide in metastatic prostate cancer before chemotherapy.
|
N Engl J Med
|
2014
|
11.05
|
|
8
|
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
|
Lancet Oncol
|
2012
|
6.49
|
|
9
|
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
|
J Clin Oncol
|
2010
|
5.86
|
|
10
|
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.
|
Clin Cancer Res
|
2007
|
5.36
|
|
11
|
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
|
J Clin Oncol
|
2010
|
4.64
|
|
12
|
Differential exoprotease activities confer tumor-specific serum peptidome patterns.
|
J Clin Invest
|
2006
|
4.37
|
|
13
|
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
|
Cancer Cell
|
2002
|
4.34
|
|
14
|
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration.
|
J Clin Oncol
|
2002
|
3.93
|
|
15
|
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
|
J Clin Oncol
|
2007
|
3.91
|
|
16
|
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
|
Lancet Oncol
|
2012
|
3.82
|
|
17
|
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.
|
Lancet Oncol
|
2006
|
3.75
|
|
18
|
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
|
Clin Cancer Res
|
2002
|
3.72
|
|
19
|
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.
|
Clin Cancer Res
|
2005
|
3.71
|
|
20
|
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
|
Clin Cancer Res
|
2009
|
3.61
|
|
21
|
Portable filter-based microdevice for detection and characterization of circulating tumor cells.
|
Clin Cancer Res
|
2010
|
3.61
|
|
22
|
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy.
|
J Clin Oncol
|
2007
|
3.60
|
|
23
|
Targeting the androgen receptor pathway in prostate cancer.
|
Curr Opin Pharmacol
|
2008
|
3.56
|
|
24
|
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.
|
Clin Cancer Res
|
2007
|
3.53
|
|
25
|
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.
|
J Clin Invest
|
2010
|
3.47
|
|
26
|
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.
|
Lancet Oncol
|
2009
|
3.13
|
|
27
|
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.
|
Eur Urol
|
2009
|
3.11
|
|
28
|
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.
|
Proc Natl Acad Sci U S A
|
2002
|
2.69
|
|
29
|
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.
|
J Clin Oncol
|
2013
|
2.57
|
|
30
|
ARN-509: a novel antiandrogen for prostate cancer treatment.
|
Cancer Res
|
2012
|
2.51
|
|
31
|
Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.
|
Clin Cancer Res
|
2007
|
2.50
|
|
32
|
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
|
Clin Cancer Res
|
2007
|
2.50
|
|
33
|
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature.
|
Eur Urol
|
2013
|
2.46
|
|
34
|
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.
|
Cancer Res
|
2009
|
2.42
|
|
35
|
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.
|
Lancet Oncol
|
2012
|
2.31
|
|
36
|
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.
|
Eur Urol
|
2012
|
2.27
|
|
37
|
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
|
J Clin Oncol
|
2012
|
2.26
|
|
38
|
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.
|
Nat Med
|
2013
|
2.26
|
|
39
|
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.
|
Radiology
|
2013
|
2.24
|
|
40
|
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.
|
Lancet Oncol
|
2012
|
2.24
|
|
41
|
Circulating tumor cells as biomarkers in prostate cancer.
|
Clin Cancer Res
|
2011
|
2.17
|
|
42
|
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
|
Eur Urol
|
2011
|
2.14
|
|
43
|
Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging.
|
Radiology
|
2004
|
2.13
|
|
44
|
Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
|
Oncology (Williston Park)
|
2014
|
2.12
|
|
45
|
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
|
Cancer Res
|
2003
|
2.04
|
|
46
|
Considerations in the development of circulating tumor cell technology for clinical use.
|
J Transl Med
|
2012
|
2.00
|
|
47
|
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials.
|
Nat Clin Pract Oncol
|
2006
|
1.99
|
|
48
|
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.
|
Clin Cancer Res
|
2005
|
1.97
|
|
49
|
The progress and promise of molecular imaging probes in oncologic drug development.
|
Clin Cancer Res
|
2005
|
1.97
|
|
50
|
The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer.
|
Cancer
|
2003
|
1.91
|
|
51
|
Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities.
|
J Am Med Inform Assoc
|
2007
|
1.89
|
|
52
|
Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling.
|
Nat Commun
|
2011
|
1.84
|
|
53
|
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse.
|
Cancer Res
|
2003
|
1.81
|
|
54
|
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
|
Clin Cancer Res
|
2012
|
1.78
|
|
55
|
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
|
J Clin Oncol
|
2008
|
1.71
|
|
56
|
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.
|
Cancer Res
|
2012
|
1.71
|
|
57
|
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.
|
Cancer Res
|
2009
|
1.68
|
|
58
|
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.
|
Clin Cancer Res
|
2009
|
1.68
|
|
59
|
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
|
Clin Cancer Res
|
2010
|
1.68
|
|
60
|
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.
|
Eur Urol
|
2011
|
1.64
|
|
61
|
Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy.
|
Clin Cancer Res
|
2005
|
1.64
|
|
62
|
A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.
|
Int J Cancer
|
2012
|
1.60
|
|
63
|
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.
|
Urology
|
2002
|
1.57
|
|
64
|
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
|
J Clin Oncol
|
2005
|
1.54
|
|
65
|
2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy.
|
Clin Cancer Res
|
2005
|
1.53
|
|
66
|
Quantifying the amount of variation in survival explained by prostate-specific antigen.
|
Clin Cancer Res
|
2002
|
1.52
|
|
67
|
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
|
Clin Cancer Res
|
2013
|
1.51
|
|
68
|
Second-line chemotherapy for prostate cancer: patient characteristics and survival.
|
Clin Prostate Cancer
|
2005
|
1.49
|
|
69
|
Locally advanced prostate cancer: a population-based study of treatment patterns.
|
BJU Int
|
2011
|
1.46
|
|
70
|
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
|
Cancer
|
2004
|
1.45
|
|
71
|
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.
|
J Clin Oncol
|
2004
|
1.44
|
|
72
|
Enzalutamide in European and North American men participating in the AFFIRM trial.
|
BJU Int
|
2014
|
1.43
|
|
73
|
Hsp90 as a therapeutic target in prostate cancer.
|
Semin Oncol
|
2003
|
1.42
|
|
74
|
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
|
J Clin Oncol
|
2007
|
1.41
|
|
75
|
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.
|
Clin Cancer Res
|
2010
|
1.40
|
|
76
|
The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations.
|
Pain Med
|
2010
|
1.40
|
|
77
|
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
|
J Clin Oncol
|
2005
|
1.39
|
|
78
|
The natural history of noncastrate metastatic prostate cancer after radical prostatectomy.
|
Eur Urol
|
2006
|
1.38
|
|
79
|
p27 as a target for cancer therapeutics.
|
Cancer Cell
|
2003
|
1.38
|
|
80
|
Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
|
J Clin Oncol
|
2003
|
1.37
|
|
81
|
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.
|
Clin Cancer Res
|
2005
|
1.36
|
|
82
|
Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.
|
Clin Chem
|
2009
|
1.36
|
|
83
|
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
|
J Clin Oncol
|
2009
|
1.36
|
|
84
|
Improved prediction of prostate cancer recurrence through systems pathology.
|
J Clin Invest
|
2007
|
1.35
|
|
85
|
NF-kappaB regulates androgen receptor expression and prostate cancer growth.
|
Am J Pathol
|
2009
|
1.35
|
|
86
|
Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy.
|
J Clin Oncol
|
2005
|
1.35
|
|
87
|
Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy.
|
J Clin Oncol
|
2013
|
1.34
|
|
88
|
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
|
Mol Cancer Ther
|
2007
|
1.32
|
|
89
|
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
|
Cancer Chemother Pharmacol
|
2010
|
1.32
|
|
90
|
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).
|
J Neurooncol
|
2008
|
1.31
|
|
91
|
Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET.
|
J Nucl Med
|
2010
|
1.27
|
|
92
|
Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
|
J Nucl Med
|
2002
|
1.26
|
|
93
|
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems.
|
Vaccine
|
2004
|
1.25
|
|
94
|
Circulating tumors cells as biomarkers: progress toward biomarker qualification.
|
Cancer J
|
2011
|
1.25
|
|
95
|
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
|
J Clin Oncol
|
2013
|
1.21
|
|
96
|
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.
|
Clin Cancer Res
|
2007
|
1.20
|
|
97
|
Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha.
|
Cancer Res
|
2007
|
1.20
|
|
98
|
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.
|
Eur J Nucl Med Mol Imaging
|
2013
|
1.20
|
|
99
|
Susceptibility loci associated with prostate cancer progression and mortality.
|
Clin Cancer Res
|
2010
|
1.19
|
|
100
|
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
|
Clin Cancer Res
|
2002
|
1.19
|
|
101
|
Androgen receptor antagonists in castration-resistant prostate cancer.
|
Cancer J
|
2013
|
1.19
|
|
102
|
Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
|
Urology
|
2006
|
1.18
|
|
103
|
Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT.
|
J Nucl Med
|
2011
|
1.18
|
|
104
|
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
|
Clin Genitourin Cancer
|
2009
|
1.17
|
|
105
|
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.
|
Clin Cancer Res
|
2005
|
1.17
|
|
106
|
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
|
Clin Cancer Res
|
2002
|
1.16
|
|
107
|
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
|
J Clin Oncol
|
2008
|
1.16
|
|
108
|
Identification of novel androgen receptor target genes in prostate cancer.
|
Mol Cancer
|
2007
|
1.15
|
|
109
|
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.
|
J Nucl Med
|
2008
|
1.15
|
|
110
|
Critical function for ADAM9 in mouse prostate cancer.
|
Cancer Res
|
2005
|
1.14
|
|
111
|
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
|
J Clin Oncol
|
2007
|
1.14
|
|
112
|
Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease.
|
BJU Int
|
2009
|
1.13
|
|
113
|
Computer-aided quantitative bone scan assessment of prostate cancer treatment response.
|
Nucl Med Commun
|
2012
|
1.13
|
|
114
|
Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events.
|
Mol Carcinog
|
2004
|
1.13
|
|
115
|
Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
|
Cancer Immunol Immunother
|
2005
|
1.12
|
|
116
|
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
|
Eur J Nucl Med Mol Imaging
|
2014
|
1.10
|
|
117
|
Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.
|
Nat Rev Drug Discov
|
2013
|
1.10
|
|
118
|
Developing imaging strategies for castration resistant prostate cancer.
|
Acta Oncol
|
2011
|
1.10
|
|
119
|
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
|
J Urol
|
2007
|
1.07
|
|
120
|
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.
|
Int J Cancer
|
2005
|
1.07
|
|
121
|
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.05
|
|
122
|
Rapid androgen cycling as treatment for patients with prostate cancer.
|
Clin Cancer Res
|
2006
|
1.03
|
|
123
|
β4 Integrin signaling induces expansion of prostate tumor progenitors.
|
J Clin Invest
|
2013
|
1.03
|
|
124
|
Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.
|
Cancer Res
|
2003
|
1.02
|
|
125
|
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
|
Clin Cancer Res
|
2006
|
1.02
|
|
126
|
Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.
|
J Clin Oncol
|
2005
|
1.02
|
|
127
|
Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.
|
Mol Cancer Ther
|
2004
|
1.01
|
|
128
|
DNA vaccines: an active immunization strategy for prostate cancer.
|
Semin Oncol
|
2003
|
1.01
|
|
129
|
HER-2 profiling and targeting in prostate carcinoma.
|
Cancer
|
2002
|
1.01
|
|
130
|
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
|
Clin Cancer Res
|
2002
|
0.99
|
|
131
|
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.
|
Eur J Cancer
|
2013
|
0.98
|
|
132
|
Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data.
|
Med Decis Making
|
2007
|
0.97
|
|
133
|
A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.
|
Vaccine
|
2005
|
0.96
|
|
134
|
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.
|
Cancer Chemother Pharmacol
|
2011
|
0.96
|
|
135
|
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.
|
Clin Cancer Res
|
2010
|
0.95
|
|
136
|
Novel mutations of epidermal growth factor receptor in localized prostate cancer.
|
Front Biosci
|
2006
|
0.94
|
|
137
|
Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI).
|
J Pain Symptom Manage
|
2010
|
0.94
|
|
138
|
Imaging therapeutic response in human bone marrow using rapid whole-body MRI.
|
Magn Reson Med
|
2004
|
0.93
|
|
139
|
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?".
|
Cancer Immunol Immunother
|
2007
|
0.93
|
|
140
|
Glutathione S-transferase P1 Ile105Val polymorphism, cigarette smoking and prostate cancer.
|
Cancer Detect Prev
|
2004
|
0.93
|
|
141
|
(11)C-acetate PET imaging in prostate cancer.
|
Eur J Nucl Med Mol Imaging
|
2007
|
0.93
|
|
142
|
Prostate cancer: a dynamic illness with shifting targets.
|
Lancet Oncol
|
2003
|
0.92
|
|
143
|
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
|
Cancer
|
2003
|
0.91
|
|
144
|
Advances in imaging in the postoperative patient with a rising prostate-specific antigen level.
|
Semin Oncol
|
2003
|
0.91
|
|
145
|
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.
|
Curr Treat Options Oncol
|
2012
|
0.89
|
|
146
|
Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer.
|
Clin Genitourin Cancer
|
2009
|
0.89
|
|
147
|
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2011
|
0.89
|
|
148
|
Prostate cancer in 2011: Hitting old targets better and identifying new targets.
|
Nat Rev Clin Oncol
|
2012
|
0.88
|
|
149
|
Prostate-specific antigen as a marker of disease activity in prostate cancer.
|
Oncology (Williston Park)
|
2002
|
0.88
|
|
150
|
Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer.
|
PLoS One
|
2010
|
0.88
|
|
151
|
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.88
|
|
152
|
Outcome predictions for patients with metastatic prostate cancer.
|
Semin Urol Oncol
|
2002
|
0.88
|
|
153
|
Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel.
|
Cancer
|
2008
|
0.88
|
|
154
|
A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.
|
Vaccine
|
2012
|
0.87
|
|
155
|
Prostate cancer topography and patterns of lymph node metastasis.
|
Am J Surg Pathol
|
2010
|
0.86
|
|
156
|
Decreased retinoid X receptor-alpha protein expression in basal cells occurs in the early stage of human prostate cancer development.
|
Cancer Epidemiol Biomarkers Prev
|
2004
|
0.86
|
|
157
|
Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen.
|
Urology
|
2005
|
0.86
|
|
158
|
Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements.
|
Acta Oncol
|
2002
|
0.85
|
|
159
|
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors.
|
Clin Cancer Res
|
2007
|
0.84
|
|
160
|
Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer.
|
Appl Immunohistochem Mol Morphol
|
2005
|
0.84
|
|
161
|
Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?
|
Semin Oncol
|
2013
|
0.84
|
|
162
|
Clinical approaches to osseous metastases in prostate cancer.
|
Oncologist
|
2003
|
0.82
|
|
163
|
Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
|
Int J Cancer
|
2009
|
0.81
|
|
164
|
Detection of androgen receptor mutations in circulating tumor cells: highlights of the long road to clinical qualification.
|
Clin Chem
|
2010
|
0.81
|
|
165
|
A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin.
|
Endocrinology
|
2009
|
0.81
|
|
166
|
Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies.
|
Surg Oncol
|
2002
|
0.81
|
|
167
|
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building.
|
J Pharmacokinet Pharmacodyn
|
2012
|
0.80
|
|
168
|
Expression of prostate-specific membrane antigen in renal cortical tumors.
|
Mod Pathol
|
2008
|
0.80
|
|
169
|
Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.
|
Clin Chem Lab Med
|
2012
|
0.78
|
|
170
|
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.
|
J Oncol Pract
|
2013
|
0.78
|
|
171
|
Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients.
|
Cancer J
|
2016
|
0.78
|
|
172
|
Finding the place of histone deacetylase inhibitors in prostate cancer therapy.
|
Expert Rev Clin Pharmacol
|
2009
|
0.77
|
|
173
|
Bone marrow aspiration for disseminated tumor cell detection: a must-have test or is the jury still out?
|
J Clin Oncol
|
2009
|
0.76
|
|
174
|
Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
|
Urology
|
2004
|
0.76
|
|
175
|
Circulating cancer cells and their clinical applications.
|
Clin Chem
|
2011
|
0.76
|
|
176
|
Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?
|
J Clin Oncol
|
2005
|
0.75
|
|
177
|
Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.
|
Cancer
|
2013
|
0.75
|
|
178
|
Response.
|
Radiology
|
2015
|
0.75
|
|
179
|
Editorial: States and state transitions are all that really matter.
|
J Urol
|
2002
|
0.75
|
|
180
|
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.75
|
|
181
|
Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.
|
Curr Oncol Rep
|
2004
|
0.75
|
|
182
|
Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center.
|
Crit Rev Oncol Hematol
|
2003
|
0.75
|
|
183
|
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
|
Nat Med
|
2017
|
0.75
|
|
184
|
Prostate-specific antigen as a marker of disease activity in prostate cancer.
|
Oncology (Williston Park)
|
2002
|
0.75
|
|
185
|
Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial.
|
Urology
|
2003
|
0.75
|
|
186
|
Integrative Clinical Genomics of Advanced Prostate Cancer.
|
Cell
|
2015
|
0.75
|
|
187
|
Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.
|
Curr Urol Rep
|
2005
|
0.75
|
|
188
|
Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT.
|
Clin Nucl Med
|
2017
|
0.75
|
|
189
|
Drug development for noncastrate prostate cancer in a changed therapeutic landscape.
|
Nat Rev Clin Oncol
|
2017
|
0.75
|